Stay updated with breaking news from Jacobm Chacko. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half...
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) reported a loss for the fourth quarter on Monday.
Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse...